Skip to main content
S&P 5007,560.43+0.25%DOW51,673.98-0.60%NASDAQ25,326.24+0.64%BTC$77,210.00-0.82%ETH$2,285.09-0.14%GOLD$3,953.30-0.41%OIL$96.14-0.33%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANIX

Anixa Biosciences, Inc.

Healthcare · Biotechnology

$2.99

Up+$0.09 (+2.95%)

Updated Nov 3, 2026, 2:43 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
99.47M
P/E ratio
-8.85
Dividend yield
0.00%
52-week range
$2.32 – $5.46
Volume
128.34K
Avg. volume
307.4K

Price performance · ANIX

ANIX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ANIX closed at $2.99 after 21 trading sessions, up 1.36% for the selected period.

Last close
$2.99
Period change
+1.36%
Period low
$2.61
Period high
$3.37
Daily close
View OHLC price history
ANIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$3.14$3.1513$2.98$2.99128.34K
Oct 30, 2026$3.28$3.35$3.10$3.12140.66K
Oct 29, 2026$3.40$3.4394$3.28$3.30136.58K
Oct 28, 2026$3.26$3.43$3.20$3.37251.54K
Oct 27, 2026$2.95$3.34$2.945$3.28497.9K
Oct 26, 2026$2.94$2.98$2.89$2.93135.64K
Oct 23, 2026$2.80$3.14$2.74$2.99326.69K
Oct 22, 2026$2.70$2.78$2.68$2.78156.81K
Oct 21, 2026$2.68$2.746$2.655$2.71115.73K
Oct 20, 2026$2.64$2.75$2.64$2.68166.8K
Oct 19, 2026$2.67$2.69$2.60$2.6191.27K
Oct 16, 2026$2.79$2.8199$2.645$2.67123.53K
Oct 15, 2026$2.66$2.79$2.63$2.78223.34K
Oct 14, 2026$2.75$2.818$2.63$2.655228.44K
Oct 13, 2026$2.84$2.8401$2.66$2.67175.82K
Oct 12, 2026$2.90$2.92$2.83$2.8497.74K
Oct 9, 2026$2.93$2.96$2.86$2.90217.88K
Oct 8, 2026$2.93$2.93$2.86$2.91259.95K
Oct 7, 2026$3.01$3.0559$2.93$2.95245.25K
Oct 6, 2026$2.95$3.11$2.87$3.02344.96K
Oct 5, 2026$2.98$2.99$2.875$2.95369.46K

Latest ANIX news

The latest Smart Investors Daily articles mentioning ANIX.

Stock researchCompany · Overview

ANIX research

Overview

Company profile and research snapshot.

Company profile

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.83
Implied upside
—
Analysts
10
ANIX recent ratings
DateFirmRatingTarget
Sep 22, 2026HC Wainwright & Co.Buy—
Apr 8, 2026D. Boral CapitalBuy—
Mar 31, 2026D. Boral CapitalBuy—
Feb 4, 2026D. Boral CapitalBuy—
Dec 12, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt"). The sixth cohort is expected to commence following a routi

Yahoo · Oct 13, 2026

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

Learn how Anixa is advancing two clinical-stage oncology programs through differentiated immunotherapy and vaccine approachesManagement to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and upcoming milestonesORLANDO, FL / ACCESS Newswire / October 13, 2026 / RedChip Companies will host an investor webinar on Tuesday, October 20, 2026, at 4:15 p. ET with Anixa Biosciences, Inc.

Yahoo · Oct 13, 2026

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference. The conference, hosted by Mayo Clinic and University of Minnesota, will be held November 2–3, 2026, in Rochester, Minnesota.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By